To Get Full Access :

aBLA Filing Intelligence & Biosimilar Opportunity

Ngenla

Somatrogon-Ghla
Hormonal Therapy
Prefilled Injection

Ngenla is an injection of long-acting growth hormone, administered once a week, for children 3 years and older with growth hormone deficiency. It helps support normal growth using a prefilled pen system.

Approval Date
27-Jun-23
Data Exclusivity Expiry
27-Jun-27
Market Exclusivity Expiry
27-Jun-35
Commercial snapshot

Market performance & projections

Revenue ($M)
NA
CAGR (%)
NA
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
128
2027
155
2028
193
2029
230
2030
260
2031
292
2032
317
Molecule profile

Details & specifications

Molecule
Somatrogon-Ghla
Innovator
OPKO/PFIZER
Dosage Form
Prefilled Injection
Strength
24 mg and 60 mg
Therapeutic Category
Hormonal Therapy
Usage
To treat growth failure due to inadequate secretion of endogenous growth hormone
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.
Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data
Milestones tracked against primary FDA sources and refreshed continuously.
Analyst-built projections
Seven-year sales outlooks modeled by our pharma intelligence team.
First-to-file focus
Exclusivity windows framed around the decisions generics teams actually make.
Partnership on demand
From API sourcing to dossier support — one request starts the conversation.

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?